An Open-label Phase 1b Study of E7090 Monotherapy and in Combination With Other Anticancer Agents in Subjects With ER+, HER2- Recurrent/Metastatic Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Exemestane (Primary) ; Fulvestrant (Primary) ; Tasurgratinib (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Adverse reactions
Sponsors Eisai Co Ltd

03 Dec 2024 Planned End Date changed from 31 Dec 2024 to 31 Mar 2026.
03 Dec 2024 Planned primary completion date changed from 31 Dec 2024 to 31 Mar 2026.
04 Jun 2024 Results evaluating E7090 with/without ET in pts with ER+, HER2 negative recurrent/metastatic BC following a CDK4/6i presented at the 60th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com